Re: Rob Schott
"What effect might this have on the company?"
fortunately for all longs, SGMO has a redundant mgt structure
Sr VP Schott "is responsible for leading Sangamo's clinical development organization across all phases of drug development and regulatory approval"
Sr VP Cockroft "oversees all clinical development activities and operations"
you can't make this stuff up :-)